{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-221677","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2026-05-13T20:16:36+00:00","discovered_at":"2026-05-13T20:18:00.276681+00:00","generated_at":"2026-05-13T21:53:49.332439+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026","bullets":["Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.","Cash $379.8M as of March 31, 2026; runway into 2028.","Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.","Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.","New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-221677","json":"https://secwatch.observer/filing/0001193125-26-221677.json","markdown":"https://secwatch.observer/filing/0001193125-26-221677.md","text":"https://secwatch.observer/filing/0001193125-26-221677.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/tngx-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:53:49.332439+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2088ba885b","claim":"Kanishka Pothula resigned as Director, Member of the Nominating and Corporate Governance Committee at Tango Therapeutics, Inc..","evidence_excerpt":"Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director, Member of the Nominating and Corporate Governance Committee"}],"fact_type":"executive_change"},{"claim_id":"70fa447be4","claim":"Sung Lee was appointed as Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee at Tango Therapeutics, Inc..","evidence_excerpt":"the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee"}],"fact_type":"executive_change"},{"claim_id":"f2a371478c","claim":"Alexis Borisy resigned as Director, Lead Independent Director, Chairperson of the Compensation Committee at Tango Therapeutics, Inc..","evidence_excerpt":"On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director, Lead Independent Director, Chairperson of the Compensation Committee"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}